{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:49Z","timestamp":1786650169691,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pemphigus is comprised of a group of life-threatening autoimmune diseases that is characterized by circulating IgG antibodies targeting several types of keratinocyte antigens. After introduction of systemic steroids, survival has improved dramatically. However, mortality and morbidity were still very high due to side effects of steroids. Pulse therapy is defined as discontinuous\/intermittent intravenous infusion of very high doses of corticosteroids along with certain immunosuppressive agents over a short period. This therapy was introduced to minimize the side effects of conventional corticosteroid therapy. The target is to achieve a faster response and stronger efficacy and to decrease the need for long-term use of systemic corticosteroids. As a result, this therapy has gained its popularity since three decades. The purpose of this article is to review the various available pulse therapy regimens with dosage, indications and contraindications and side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_114_19","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T01:06:00Z","timestamp":1553735160000},"page":"793-798","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Pulse therapy"],"prefix":"10.4103","volume":"8","author":[{"given":"Subhasish","family":"Mustafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhita","family":"Hore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadeep","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20260109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/08916934.2011.606444","article-title":"Pemphigus autoimmunity: Hypotheses and realities","volume":"45","author":"Grando","year":"2012","journal-title":"Autoimmunity"},{"key":"R2-5-20260109","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/0378-6323.136832","article-title":"Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus","volume":"80","author":"Londhe","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R3-5-20260109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/CDR.CDR_42_17","article-title":"Outcome of pulse therapy in pemphigus: A 10-year study","volume":"2","author":"Varala","year":"2018","journal-title":"Clin Dermatol Rev"},{"key":"R4-5-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","article-title":"Pemphigus","volume":"32","author":"Lever","year":"1953","journal-title":"Medicine (Baltimore"},{"key":"R5-5-20260109","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2133.1977.tb06141.x","article-title":"An organ culture model for the study of pemphigus acantholysis","volume":"96","author":"Michel","year":"1977","journal-title":"Br J Dermatol"},{"key":"R6-5-20260109","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/jid.1961.58","article-title":"An electron microscopic study of acanthoysis in pemphigus vulgaris","volume":"36","author":"Wilgram","year":"1961","journal-title":"J Invest Dermatol"},{"key":"R7-5-20260109","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archderm.1970.04000030031005","article-title":"An ultrastructural study of cell junctions in pemphigus vulgaris","volume":"101","author":"Hashimoto","year":"1970","journal-title":"Arch Dermatol"},{"key":"R8-5-20260109","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bjoms.2007.07.205","article-title":"Oral mucosal disease: pemphigus","volume":"46","author":"Scully","year":"2008","journal-title":"Br J Oral Maxillofac Surg"},{"key":"R9-5-20260109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.135.1.57","article-title":"Pulse intravenous cyclophosmamide therapy in pemphigus","volume":"135","author":"Fleischli","year":"1999","journal-title":"Arch Dermatol"},{"key":"R10-5-20260109","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/0019-5154.182428","article-title":"Pulse therapy in pemphigus: Ready reckoner","volume":"61","author":"Abraham","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R11-5-20260109","first-page":"1","article-title":"Pulse therapy: A boon or bane","volume":"3","author":"Panat","year":"2012","journal-title":"J Dent Sci Oral Rehabil"},{"key":"R12-5-20260109","first-page":"26","article-title":"Pulse therapy: A decisive treatment modality in dermatological disorders","volume":"6","author":"Tarani","year":"2016","journal-title":"Indian J Appl Res"},{"key":"R13-5-20260109","first-page":"329","article-title":"Pulse therapy and its modifications in pemphigus: A six year study","volume":"69","author":"Rao","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-5-20260109","first-page":"144","article-title":"Pulse therapy in dermatology","volume":"1","author":"Mittal","year":"2007","journal-title":"Sri Ramachandra J Med"},{"key":"R15-5-20260109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/0378-6323.41366","article-title":"Current regimen of pulse therapy for pemphigus: Minor modifications, improved results","volume":"74","author":"Pasricha","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R16-5-20260109","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R17-5-20260109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03009740510017706","article-title":"The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: Focus on the treatment of rheumatoid arthritis","volume":"34","author":"Buttgereit","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"R18-5-20260109","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0190-9622(84)80193-0","article-title":"Cyclophosphamide: A review on relevant pharmacology and clinical uses","volume":"11","author":"Ahmed","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"R19-5-20260109","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0733-8635(05)70194-7","article-title":"Pulse intravenous cyclophosphamide therapy for dermatologic disorders","volume":"18","author":"Fox","year":"2000","journal-title":"Dermatol Clin"},{"key":"R20-5-20260109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0733-8635(18)30284-5","article-title":"Immunosupressive agents in dermatology","volume":"11","author":"Ho","year":"1993","journal-title":"Dermatol Clin"},{"key":"R21-5-20260109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0019-5154.123487","article-title":"Non comparative study on various pulse regimens (DCP, DAP and DMP) in pemphigus: Our experience","volume":"59","author":"Hassan","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R22-5-20260109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000057886","article-title":"Long term efficacy of Dexamethasone Cyclophosphamide Pulse Therapy in Pemphigus","volume":"204","author":"Kanwar","year":"2002","journal-title":"Dermatology"},{"key":"R23-5-20260109","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4103\/0378-6323.102354","article-title":"Rituximab in pemphigus","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R24-5-20260109","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1590\/S0021-75572007000700007","article-title":"Glucocorticoid therapy: Minimizing side effects","volume":"83","author":"Longui","year":"2007","journal-title":"J Pediatr (Rio J"},{"key":"R25-5-20260109","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R26-5-20260109","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R27-5-20260109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0378-6323.45235","article-title":"Pulse therapy for pemphigus: The burden of proof","volume":"75","author":"Singh","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R28-5-20260109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0378-6323.45236","article-title":"Prolonged antimicrobial and oral cyclophosphamide therapy in pemphigus: Need for caution","volume":"75","author":"Ramam","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R29-5-20260109","first-page":"1","article-title":"Pulse versus oral methylprednisolone therapy in pemphigus vulgaris","volume":"10","author":"Shahidi-Dadras","year":"2007","journal-title":"Arch Iran Med"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01697686-201908030-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:05:15Z","timestamp":1786647915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01697686-201908030-00005"}},"subtitle":["Opening new vistas in treatment of pemphigus"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_114_19","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}